
Abzyme Therapeutics LLC Profile last edited on: 10/7/22
CAGE: 62ES6
UEI: H2MLEFWV36N6
Business Identifier: Developing antibodies for diagnostic and therapeutic applications Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
321 Jones Boulevard Suite 300
Royersford, PA 19468
Royersford, PA 19468
(610) 990-7531 |
info@abzymetx.com |
www.abzymetx.com |
Location: Single
Congr. District: 04
County: Montgomery
Congr. District: 04
County: Montgomery
Public Profile
Using proprietary protein evolution platforms and intracellular (iHuMab) and extracellular (eHuMab) genetic selection systems, Abzyme Therapeutics LLC is organized around generating and developing full-sized human monoclonal antibodies for treating a broad range of diseases. The firm has the capabilities of generating a highly diversified human antibody repertoire and establishing a tightly regulated selection system to isolate a single antigen-specific antibody-producing clone from billions. Abzyme Therapeutics is developing a pipeline of novel, targeted human monoclonal antibodies for the treatment of Alzheimerâs disease, cancer, autoimmune diseases, and infectious diseases. Led by an interdisciplinary team of successful industry professionals, Abzyme is introducing a pioneer technology to generate human monoclonal antibodies and exploit the enormous potential of antibody-based medicines.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NIH | $299,999 | |
Project Title: Novel immune-escape uricase for treatment of hyperuricemia | ||||
2021 | 1 | NIH | $399,107 | |
Project Title: Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis | ||||
2019 | 1 | NIH | $280,352 | |
Project Title: Pemphigus-Specific T Cell Engagers for Pemphigus Targeted Immunotherapy | ||||
2019 | 1 | NIH | $299,989 | |
Project Title: Multi-Specific Long-Acting Antibodies for the Treatment of Retinal Neovascular Diseases | ||||
2019 | 1 | NIH | $299,815 | |
Project Title: Antibody Fragments to Improve HIV gp120 Protein Production |
Key People / Management
Hiep T Tran -- President and Chief Scientific Officer
Steve Manobianci -- Director of Business Development
Andrew Phillips -- Research Scientist
Rajesh Kumar Singh -- Lab Director
Rolf Swoboda
Alexander H Taylor -- Director Pre-Clinical studies
Kirill Volkov -- Senior Scientist
Steve Manobianci -- Director of Business Development
Andrew Phillips -- Research Scientist
Rajesh Kumar Singh -- Lab Director
Rolf Swoboda
Alexander H Taylor -- Director Pre-Clinical studies
Kirill Volkov -- Senior Scientist
Company News
There are no news available.